Bcl-2 overexpression does not prevent but retards adriamycin toxicity in CC531 colon carcinoma cells

Chemotherapy

Volumn 49, Issue 6, 2003, Pages 309-315

  Hoetelmans, Rob W M ^a,c   Vahrmeijer, Alexander L ^a   Mulder, Gerard J ^b   Van De Velde, Cornelius J H ^a   Nagelkerke, J Fred ^b   Van Dierendonck, Jan Hein ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c GSK   (Netherlands)

Author keywords

Adriamycin; Bcl 2; Glutathione; Growth activity

Indexed keywords

DOXORUBICIN; GLUTATHIONE; PROTEIN BCL 2;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL DEATH; CELL LINE; CELL POPULATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CELL DEATH; COLONIC NEOPLASMS; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0345215753     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074532     Document Type: Article

References (29)

1. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-1443.
2. Reed JC: Bcl-2 family proteins: Strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997;41:501-532.
3. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
4. Brenner C, Cadiou H, Vieira HL, Zamzami N, Marzo I, Xie Z, Leber B, Andrews D, Duclohier H, Reed JC, Kroemer G: Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene 2000;19:329-336.
5. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136.
6. Korsmeyer SJ: Bcl-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1693-1700.
7. Shibasaki F, Kondo E, Akagi T, McKeon F: Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997;386:728-731.
8. Hour TC, Chen L, Lin JK: Suppression of transcription factor NF-kappaB activity by Bcl-2 protein in NIH3T3 cells: Implication of a novel NF-kappa B p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2. Eur J Cell Biol 2000;79:121-129.
9. Huang DC, O'Reilly LA, Strasser A, Cory S: The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997;16:4628-4638.
10. McDonnell TJ, Nunez G, Platt FM, Hockenberry D, London L, McKearn JP, Korsmeyer SJ: Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 1990;10:1901-1907.
11. Hoetelmans RWM, Vahrmeijer AL, Van Vlierberghe RLP, Keijzer R, Van de Velde CJH, Mulder GJ, Van Dierendonck JH: The role of various Bcl-2 domains in the anti-proliferative effect and modulation of cellular glutathione levels: A prominent role for the BH4 domain. Cell Prolif 2003;36:35-44.
12. Mazel S, Burtrum D, Petrie HT: Regulation of cell division cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J Exp Med 1996;183: 2219-2226.
13. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4:327-332.
14. Meredith MJ, Cusick CL, Soltaninassab S, Sekhar KS, Lu S, Freeman ML: Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Biochem Biophys Res Commun 1998;248:458-463.
15. Rimpler MM, Rauen U, Schmidt T, Moroy T, De Groot H: Protection against hydrogen peroxide cytotoxicity in rat-1 fibroblasts provided by the oncoprotein Bcl-2. Maintenance of calcium homeostasis is secondary to the effect of Bcl-2 on cellular glutathione. Biochem J 1999; 340:291-297.
16. Schor NF, Rudin CM, Hartman AR, Thompson CB, Tyurina YY, Kagan VE: Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene 2000;19:472-476.
17. Tew KD: Gultathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54:4313-4320.
18. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF: Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985;34:2583-2586.
19. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
20. McPherson JP, Deffie AM, Jones NR, Brown GA, Deuchars KL, Goldenberg GJ: Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoiso-merase II alpha. Anticancer Res 1997;17: 4243-4252.
21. Brown JM, Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-1399.
22. Van Slooten HJ, Van de Vijver MJ, Van de Velde CJ, Van Dierendonck JH: Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998;77:789-796.
23. Vahrmeijer L, Hoetelmans RWM, Mulder GJ, Schutrups J, Vlierberghe RLP, van de Velde CJH, Van Dierendonck JH: Development of resistance to glutathione depletion-induced cell death in CC531 colon carcinoma cells: Association with increased expression of Bcl-2. Biochem Pharmacol 2000;59:1557-1562.
24. Brady HJ, Gil-Gomez G, Kirberg J, Berns AJ: Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J 1996; 15:6991-7001.
25. Fujieda S, Inuzuka M, Tanaka N, Sunaga H, Fan GK, Ito T, Sugimoto C, Tsuzuki H, Saito H: Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999;84:315-320.
26. Allouche M, Bettaieb A, Vindis C, Rousse A, Grignon C, Laurent G: Influence of Bcl-2 over-expression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene 1997;14:1837-1845.
27. Yin DX, Schimke RT: Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 1995;55:4922-4928.
28. Elliott MJ, Stribinskiene L, Lock RB: Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. Cancer Chemother Pharmacol 1998;41:457-463.
29. Kyprianou N, King ED, Bradbury D, Rhee JG: Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-348.